Home/Immix Biopharma/Ilya Rachman

IR

Ilya Rachman

Chief Executive Officer

Immix Biopharma

Therapeutic Areas

Oncology Hematology Autoimmune Diseases Rare Diseases

Immix Biopharma Pipeline

Drug	Indication	Phase
NXC-201 (formerly HBI0101)	Relapsed/Refractory AL Amyloidosis	Phase 2
NXC-201	Undisclosed Other Serious Diseases (Autoimmune/Immune-mediated)	Phase 1 / Phase 2
Undisclosed Cell Therapy	Undisclosed	Pre-clinical

Leadership Team at Immix Biopharma

Chief Commercial Officer

Chief Financial Officer

Senior Clinical Development & Regulatory Advisor

View full Immix Biopharma profile